Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06017089 · ClinicalTrials.gov registry record · NA

The Pediatric Artificial Pancreas Automated Initialization Trial

A NA study of Type 1 Diabetes, sponsored by Marc Breton.

Completed
Registry status
NA
Development phase
33
Enrollment target
3
Study locations

NCT06017089 is a NA study of Type 1 Diabetes that has completed, run by Marc Breton. The registered enrollment target is 33 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06017089, a NA study of Type 1 Diabetes, has completed, sponsored by Marc Breton.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target
3
Study locations

Study Summary

The goal of this clinical trial is to obtain safety data and exploratory glycemic control data from use of an at-home closed loop control (CLC) system (t:slim X2 with Control-IQ Technology) with periodic parameter adjustments driven by an AI-based Advisor system in young children with Type 1 Diabetes. The main endpoints this study aims to answer is the safety and efficacy of the use of the AI-driven pump parameters. Participants will use the study system (pump and Continuous Glucose Monitor) in closed-loop mode for eight weeks.

Conditions Studied

Interventions

  • DEVICE AI-based Advisor system

Study Locations (3)

California

  • Stanford University - Stanford

Colorado

  • Barbara Davis Center, University of Colorado - Aurora

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2023-11-10
Est. Completion 2024-06-17
Phase NA

Sponsor

Marc Breton

6 total trials

What the Registry Record Tells You About NCT06017089

The ClinicalTrials.gov registry entry for NCT06017089 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (96% lower). The listed sponsor is Marc Breton, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which AI-based Advisor system is the first listed.

NCT06017089 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Virginia.

Frequently Asked Questions

What is clinical trial NCT06017089 about?

NCT06017089 is a clinical study titled "The Pediatric Artificial Pancreas Automated Initialization Trial". The goal of this clinical trial is to obtain safety data and exploratory glycemic control data from use of an at-home closed loop control (CLC) system (t:slim X2 with Control-IQ Technology) with periodic parameter adjustments driven by an AI-based Advisor system in young children with Type 1 Diabete...

What is the current status of trial NCT06017089?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2023-11-10. Estimated completion is 2024-06-17.

What conditions does trial NCT06017089 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT06017089?

The interventions under investigation include: AI-based Advisor system (DEVICE).

Who is sponsoring clinical trial NCT06017089?

This trial is sponsored by Marc Breton, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06017089 being conducted?

This trial has 3 study locations across California, Colorado, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.